First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped 1. Very low enrollment rate. 2. Recent studies question the effect of adding panitumumab in this category of patients. 3. Too high toxicity rate

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Carboplatin
DRUG: Vinorelbine
DRUG: panitumumab

Sponsor

Vejle Hospital